Abstract
Several long non-coding RNAs (lncRNAs) have been identified that may have a crucial role in tumor progression and metastasis. The lncRNA cancer susceptibility candidate2 (CASC2) has previously been reported to act as a tumor suppressor gene in glioma and colorectal cancer. However, the expression and function of CASC2 in renal cell carcinoma (RCC) remains to be elucidated. The present study confirmed that CASC2 was downregulated in human RCC tissues and human RCC cell lines (786‑O and A498). Restoration of CASC2 expression via transfection with a pcDNA3.1(+)‑CASC2 vector was able to inhibit cell proliferation and migration in 786‑O and A498 cells, as compared with in the cells transfected with a pcDNA3.1(+) empty vector. MicroRNA‑21 (miR‑21) has been reported to be upregulated in human RCC tissues and cell lines, and is associated with the malignant progression of RCC. In the present study, bioinformatics analysis and dual‑luciferase reporter assays confirmed that CASC2 was a direct target gene of miR‑21. miR‑21 was able to decrease the expression of CASC2 in 786‑O and A498 cells. Furthermore, overexpression of miR‑21 partly abrogated CASC2‑mediated inhibition of 786‑O and A498 cell proliferation and migration. The present study provides evidence indicating that CASC2 targeted by miR‑21 acts as a tumor suppressor in RCC. Therefore, CASC2 may be considered a novel target for the diagnosis and treatment of RCC.
Highlights
Renal cell carcinoma (RCC) is a type of highly metastasized tumor that accounts for 3% of all malignancies in adults
The long non‐coding RNA cancer susceptibility candidate 2 (CASC2), which is located at chromosome 10q26, was initially reported to be downregulated in endometrial cancer, where it acted as a tumor suppressor gene [5]
Post‐transfection with the pcDNA3.1(+)‐CASC2 overexpression vector, the optical density (OD) of 786‐O cells revealed that relative cell proliferation was significantly decreased by 8.21% at 24 h, 14.22% at 48 h and 21.1% at 72 h (P= 0.001); the OD of A498 cells demonstrated that proliferation was decreased by 6.36% at 24 h, 12.46% at 48 h and 16.32% at 72 h (P=0.005; Fig. 2A)
Summary
Renal cell carcinoma (RCC) is a type of highly metastasized tumor that accounts for 3% of all malignancies in adults. The long non‐coding RNA (lncRNA) cancer susceptibility candidate 2 (CASC2), which is located at chromosome 10q26, was initially reported to be downregulated in endometrial cancer, where it acted as a tumor suppressor gene [5]. Previous studies have demonstrated that exogenous expression of CASC2 significantly inhibits the growth of undifferentiated endometrial cancer cells and suppresses glioma cell metastasis [6,7]. Little is currently known regarding the expression and function of CASC2 in RCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
